Cytosorbents (NASDAQ:CTSO) Given “Neutral” Rating at HC Wainwright

Cytosorbents (NASDAQ:CTSO)‘s stock had its “neutral” rating reaffirmed by analysts at HC Wainwright in a report released on Thursday,Benzinga reports. They currently have a $1.00 target price on the medical research company’s stock.

CTSO has been the subject of a number of other research reports. D. Boral Capital reissued a “buy” rating and set a $10.00 price target on shares of Cytosorbents in a report on Tuesday. StockNews.com initiated coverage on shares of Cytosorbents in a research note on Thursday. They issued a “hold” rating on the stock. Two analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Cytosorbents currently has a consensus rating of “Moderate Buy” and a consensus target price of $4.67.

Cytosorbents Price Performance

NASDAQ:CTSO opened at $1.00 on Thursday. The firm has a fifty day simple moving average of $1.07 and a 200 day simple moving average of $1.05. Cytosorbents has a 1-year low of $0.70 and a 1-year high of $1.61. The stock has a market capitalization of $54.68 million, a PE ratio of -2.78 and a beta of 0.78. The company has a current ratio of 1.97, a quick ratio of 1.58 and a debt-to-equity ratio of 1.06.

Cytosorbents (NASDAQ:CTSO) last announced its quarterly earnings results on Monday, March 31st. The medical research company reported ($0.03) EPS for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.04. Cytosorbents had a negative net margin of 49.47% and a negative return on equity of 118.54%. The business had revenue of $9.20 million for the quarter, compared to analyst estimates of $10.09 million. On average, research analysts expect that Cytosorbents will post -0.3 EPS for the current fiscal year.

Institutional Investors Weigh In On Cytosorbents

Hedge funds have recently added to or reduced their stakes in the business. Renaissance Technologies LLC raised its stake in shares of Cytosorbents by 10.6% during the fourth quarter. Renaissance Technologies LLC now owns 88,020 shares of the medical research company’s stock valued at $80,000 after acquiring an additional 8,400 shares during the last quarter. Northern Trust Corp lifted its stake in shares of Cytosorbents by 22.3% in the fourth quarter. Northern Trust Corp now owns 91,560 shares of the medical research company’s stock worth $83,000 after acquiring an additional 16,701 shares during the period. Skylands Capital LLC raised its holdings in Cytosorbents by 1.0% during the 4th quarter. Skylands Capital LLC now owns 2,781,622 shares of the medical research company’s stock worth $2,531,000 after purchasing an additional 26,195 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Cytosorbents by 7.5% during the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock worth $701,000 after buying an additional 32,415 shares during the period. Finally, Millennium Management LLC bought a new position in Cytosorbents during the fourth quarter worth $30,000. 32.87% of the stock is currently owned by institutional investors and hedge funds.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.